Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.
Kurppa KJ et al.
Plos One, 2014
Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE et al.
Biotechnology Journal, 2013
Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ et al.
The Biochemical Journal, 2011
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.
Shih AJ et al.
Cancers, 2011
Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH et al.
International Journal of Cancer, 2006
Select a paper to view details